Consistent with our data showing a correlation between MAP3K1 levels and poor prognosis in PDAC patients, MAP3K1 expression correlates with progression and poor prognosis of hormone-receptor-positive, HER2-negative early-stage breast cancer patients [93]. Here, ERBB2 is linked to breast cancer.